Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 10/20 | 0.34 |
| ▸ | MAOA | P21397 | 10/20 | 0.34 |
| ▸ | MAOB | P27338 | 10/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17827377 | 1.00 | CYP3A4 (0.39) | CYP3A4MAPK1ALDH1A1KDM4EGLA | |
| SCHEMBL18176800 | 1.00 | CYP3A4 (0.39) | CYP3A4MAPK1ALDH1A1KDM4EGLA | |
| SCHEMBL18801954 | 0.83 | CYP3A4 (0.42) | CYP3A4MAPK1ALDH1A1HCRTR2HCRTR1 | |
| SCHEMBL5326362 | 0.83 | CYP3A4 (0.38) | CYP3A4MAPK1ALDH1A1HCRTR2HCRTR1 | |
| SCHEMBL20537397 | 0.83 | CYP3A4 (0.38) | CYP3A4MAPK1ALDH1A1KDM4EGLA | |
| SCHEMBL5331015 | 0.83 | CYP3A4 (0.42) | CYP3A4MAPK1ALDH1A1HCRTR2HCRTR1 | |
| SCHEMBL16808485 | 0.83 | CYP3A4 (0.42) | CYP3A4MAPK1ALDH1A1HCRTR2HCRTR1 | |
| SCHEMBL5325290 | 0.83 | CYP3A4 (0.38) | CYP3A4MAPK1ALDH1A1HCRTR2HCRTR1 | |
| SCHEMBL14626066 | 0.83 | CYP3A4 (0.42) | CYP3A4MAPK1ALDH1A1HCRTR2HCRTR1 | |
| SCHEMBL13958487 | 0.81 | CYP3A4 (0.48) | CYP3A4MAPK1HCRTR2HCRTR1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9937145-B2 | Sulfamate derivative compound for use in preventing or treating epilepsy | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2018-04-10 | — | — | US | disclosed |
| US-20160310461-A1 | Sulfamate Derivative Compound for Use in Preventing or Treating Epilepsy | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310461-A1 | Sulfamate Derivative Compound for Use in Preventing or Treating Epilepsy | STS, SULT2A1, GRIK5 | CYP3A4 677/4885MAPK1 3065/4885ALDH1A1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.